Latest Morphine Companies Update
Oct 2023: The multinational specialty pharmaceutical business Mallinckrodt plc reported that the U.S. Bankruptcy Court for the District of Delaware has accepted its Plan of Reorganization, putting the Company in a position to exit Chapter 11 before the year is out. Most of Mallinckrodt's financial stakeholders, including the holders of the Opioid Master Disbursement Trust II and almost 90% of its first and second lien debt, support the Company's plan of reorganization. As previously stated, on September 20, 2023, the board of Mallinckrodt began the examinership process in Ireland. It is anticipated that these procedures, which are necessary to allow for the emergence and implement certain components of the Company's financial restructuring under Irish law, will take two to three months to finish.
Jan 2023: An expanded medicinal cannabis offering by Linneo Health to include industrial derivatives has been announced. Linneo Health is an international leader in the research, cultivation, and supply of cannabis to progress human health and well-being. Alcaliber is a leading self-governing dealer of intermediates and active pharmaceutical ingredients (APIs) to the worldwide pharmaceutical industry. In addition to its current line of EU-GMP-certified medicinal cannabis flowers, Linneo Health can now deliver medicinal finished dosage forms, including tetrahydrocannabinol (THC) and standardized cannabis extracts, under the terms of an exclusive CDMO agreement with Alcaliber.List of Morphine Key companies in the market
- Mallinckrodt Pharmaceuticals
- Alcaliber
- Purdue Pharma
- Sanofi Winthrop Industries
- Macfarlan Smith
- Sun Pharmaceutical Industries
- Qinghai Pharmaceutical
- Northeast Pharmaceutical Group
- Pfizer Inc.
- Verve Health Care Ltd.
- Johnson Matthey Fine Chemicals
- Manus Aktteva Biopharma LLP
- Mayne Pharma Group Limited
- Daiichi Sankyo Inc.
- Taj Pharmaceuticals Limited